福森藥業(01652.HK)料年度淨利跌逾45%
格隆匯3月16日丨福森藥業(01652.HK)公告,預期集團於2019年財政年度錄得公司擁有人應占溢利較截至2018年12月31日止年度公司擁有人應占溢利約人民幣1.02億元下跌逾45%。
董事會認為2019年財政年度業績變動乃主要基於以下因素:(1)隨着兩票制等一系列醫改政策的持續推進,行業競爭愈發激烈。集團減少與小規模經銷商合作,逐步將銷售渠道集中到全國性或區域龍頭經銷商,以及有終端銷售能力的經銷商。集團重新構建銷售體系以應對市場變化及提升其在終端市場的掌控力。在調整過程中,集團的銷量有一定波動。
(2)中藥注射液受中國境內相關政策變動影響,使用範圍進一步受到限制,令主要產品雙黃連注射液和柴胡注射液的銷售均有較大降幅。
(3)為提升集團長遠競爭力,集團持續加強研發投入,如多個項目的一致性評價,令研發費用增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.